American ginseng does not improve fatigue in multiple sclerosis: A single center randomized double-blind placebo-controlled crossover pilot study

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

This study examined the safety and efficacy of an escalating dose (100 mg, 200 mg, 400 mg/day) of American ginseng over 6 weeks in a single-center, randomized, double-blind, placebo-controlled, crossover trial with 56 subjects with multiple sclerosis and fatigue. There were no serious adverse events but fatigue on ginseng, as assessed by the Fatigue Severity Scale, was not significantly different from fatigue on placebo.

Original languageEnglish (US)
Pages (from-to)1523-1526
Number of pages4
JournalMultiple Sclerosis
Volume17
Issue number12
DOIs
StatePublished - 2011

Fingerprint

Panax
Cross-Over Studies
Multiple Sclerosis
Fatigue
Placebos
Safety

Keywords

  • clinical trial
  • complementary therapies
  • fatigue
  • ginseng
  • multiple sclerosis
  • Panax

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

@article{30dd2c3a7d3a4890b43e2e85ec6833e3,
title = "American ginseng does not improve fatigue in multiple sclerosis: A single center randomized double-blind placebo-controlled crossover pilot study",
abstract = "This study examined the safety and efficacy of an escalating dose (100 mg, 200 mg, 400 mg/day) of American ginseng over 6 weeks in a single-center, randomized, double-blind, placebo-controlled, crossover trial with 56 subjects with multiple sclerosis and fatigue. There were no serious adverse events but fatigue on ginseng, as assessed by the Fatigue Severity Scale, was not significantly different from fatigue on placebo.",
keywords = "clinical trial, complementary therapies, fatigue, ginseng, multiple sclerosis, Panax",
author = "Edward Kim and Michelle Cameron and J. Lovera and L. Schaben and Dennis Bourdette and Ruth Whitham",
year = "2011",
doi = "10.1177/1352458511412062",
language = "English (US)",
volume = "17",
pages = "1523--1526",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "12",

}

TY - JOUR

T1 - American ginseng does not improve fatigue in multiple sclerosis

T2 - A single center randomized double-blind placebo-controlled crossover pilot study

AU - Kim, Edward

AU - Cameron, Michelle

AU - Lovera, J.

AU - Schaben, L.

AU - Bourdette, Dennis

AU - Whitham, Ruth

PY - 2011

Y1 - 2011

N2 - This study examined the safety and efficacy of an escalating dose (100 mg, 200 mg, 400 mg/day) of American ginseng over 6 weeks in a single-center, randomized, double-blind, placebo-controlled, crossover trial with 56 subjects with multiple sclerosis and fatigue. There were no serious adverse events but fatigue on ginseng, as assessed by the Fatigue Severity Scale, was not significantly different from fatigue on placebo.

AB - This study examined the safety and efficacy of an escalating dose (100 mg, 200 mg, 400 mg/day) of American ginseng over 6 weeks in a single-center, randomized, double-blind, placebo-controlled, crossover trial with 56 subjects with multiple sclerosis and fatigue. There were no serious adverse events but fatigue on ginseng, as assessed by the Fatigue Severity Scale, was not significantly different from fatigue on placebo.

KW - clinical trial

KW - complementary therapies

KW - fatigue

KW - ginseng

KW - multiple sclerosis

KW - Panax

UR - http://www.scopus.com/inward/record.url?scp=82555171609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82555171609&partnerID=8YFLogxK

U2 - 10.1177/1352458511412062

DO - 10.1177/1352458511412062

M3 - Article

C2 - 21803872

AN - SCOPUS:82555171609

VL - 17

SP - 1523

EP - 1526

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 12

ER -